Dr. Pecora on CTLA-4 and PD-1 Combinations in Multiple Myeloma

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the combination of CTLA-4 and PD-1 inhibitors for the treatment of patients with multiple myeloma.

The rationale behind this combination is that CTLA-4 inhibitors are a true suppressor of T-regulatory cells. Additionally, CTLA-4 works centrally, whereas PD-1 works in the periphery, which makes this an ideal combination, explains Pecora.